A four-amino-acid peptide targeting the prostate gland—developed as a bioregulator variant with preclinical data from a rat inflammation model and unverified chromatin studies, but no controlled human trial.

Prostamax is a synthetic tetrapeptide (four amino acids) developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of Vladimir Khavinson's program to create organ-targeted peptide bioregulators. The sequence is Lys-Glu-Asp-Pro (KEDP), with a molecular weight of approximately 473 daltons.

The compound belongs to a subfamily of Khavinson peptides that all begin with the same three amino acids—lysine, glutamic acid, and aspartic acid—differing only in their C-terminal residue. Livagen ends with alanine (KEDA). Prostamax ends with proline (KEDP). Testagen ends with glycine (KEDG). Pancragen ends with tryptophan (KEDW). The claim is that this single-residue substitution redirects the peptide to different target organs and different biological effects—liver function, prostate health, testicular function, and pancreatic glucose control, respectively.

The published evidence for Prostamax is the thinnest in this subfamily. One rat prostatitis model showed reduced inflammation, swelling, and scarring. Chromatin studies reported changes in heterochromatin structure consistent with the broader Khavinson mechanism hypothesis. No English-language PubMed-indexed studies specific to Prostamax were found in exhaustive search. No human trials have been conducted or published. The related tissue-extract pharmaceutical Prostatilen (a complex mixture from prostate tissue) is approved and used in Russia—but that approved drug is not the same as the synthetic tetrapeptide Prostamax, and the existence of an approved extract does not constitute evidence for the synthetic peptide.

For readers evaluating Prostamax, the editorial context is critical. Prostate health is one of the most aggressively marketed wellness categories on the internet. Unvalidated compounds and unsupported claims proliferate. The Dutch Uncle approach requires not skepticism, but systematic refusal to claim evidence where none exists.

Quick Facts: Prostamax at a Glance

What Is Prostamax?

Pronunciation: PROSS-tah-max

Prostamax is a synthetic tetrapeptide—a molecule made of exactly four amino acids, L-lysine, L-glutamic acid, L-aspartic acid, and L-proline, joined in sequence by peptide bonds. Its molecular weight is approximately 473 Da. For comparison, BPC-157 (15 amino acids) weighs ~1419 Da. Prostamax is roughly one-third the size.

It belongs to the family of "Khavinson bioregulators"—ultrashort peptides (2–7 amino acids) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The family includes nine synthetic compounds in Peptidings Cluster S, including Vilon (2 amino acids), Thymogen (2), Vesugen (3), Livagen (4), Pancragen (4), and Prostamax (4).

The bioregulator paradigm proposes that these ultrashort peptides are not traditional receptor agonists. They do not bind G-protein-coupled receptors, ion channels, or cytokine receptors. Instead, they are proposed to enter cells, cross nuclear membranes, interact directly with DNA and histone proteins, and modulate gene expression in an organ-specific manner.

Prostamax is the prostate-targeted bioregulator in this framework—theorized to target genes involved in prostate function, vascular health, and tissue integrity that decline with age.

Origins and Discovery

Prostamax emerged from the same Soviet military research program that produced Vilon, Thymogen, and the other Khavinson bioregulators. Beginning in 1973, Vladimir Khavinson's team extracted peptide complexes from animal organs—including prostate tissue—to restore function in radiation-exposed soldiers.

The reductionist program that identified Vilon (Lys-Glu) from thymic extracts and Thymogen (Glu-Trp) from thymic peptides was applied to other tissues. From prostate tissue extracts, researchers identified a peptide sequence that they designated Prostamax (Lys-Glu-Asp-Pro). The tetrapeptide was synthesized and tested in preclinical models.

Unlike Thymogen, which achieved pharmaceutical registration in Russia (1990), Prostamax never reached formal pharmaceutical status. It remains a research compound, available through research peptide suppliers as lyophilized powder. The related tissue-extract product Prostatilen—a complex mixture extracted from prostate tissue—was registered and approved in Russia ~1990s as a pharmaceutical for prostate health. Prostatilen is not the same as the synthetic tetrapeptide Prostamax, though both come from the same research tradition.

Mechanism of Action

Prostamax's proposed mechanism is fundamentally different from conventional prostate medications (5-alpha reductase inhibitors, alpha-1 adrenergic antagonists).

The Bioregulation Hypothesis

According to the Khavinson paradigm, Prostamax (Lys-Glu-Asp-Pro) enters cells and crosses the nuclear membrane due to its small size (~473 Da). Once inside the nucleus, it is proposed to:

1. Interact with DNA — specifically with promoter regions of genes involved in prostate function 2. Bind histone proteins — modifying chromatin structure 3. Decondense heterochromatin — converting tightly packed, transcriptionally silent DNA back into open, active DNA 4. Reactivate age-silenced genes — restoring expression of prostate-specific genes that become progressively silenced with aging 5. Reduce prostate inflammation — through mechanisms not fully specified in available literature

What the Published Data Shows

The rat prostatitis model showed that a 15-day Prostamax regimen reduced prostate swelling, decreased vascular congestion (reduced blood vessel proliferation), decreased immune cell infiltration, and decreased scarring. These are inflammatory and tissue-remodeling endpoints—functional improvements in tissue health, not just gene expression changes.

Chromatin studies reported that Prostamax altered heterochromatin structure in cells from elderly individuals—increased sister chromatid exchanges, increased Ag-positive nucleolar organizer regions, and reduced pericentromeric heterochromatin. This pattern is consistent with what has been reported for Livagen (the liver-targeted tetrapeptide), suggesting a generalizable chromatin-modulating mechanism across the KEDA/KEDP/KEDG/KEDW subfamily.

The Specificity Question: Amino Acid Substitution and Organ Targeting

This is the central mechanistic challenge for Prostamax and three of its siblings. Consider this amino acid pattern:

These four tetrapeptides share three of four amino acids. They differ only at the C-terminal position. The claim is that changing alanine to proline to glycine to tryptophan redirects the peptide from liver cells to prostate cells to testicular cells to pancreatic cells—each recognizing different organ-specific DNA sequences via different binding interactions.

How does a one-residue substitution achieve this level of molecular specificity? The answer would require demonstration of differential DNA binding affinity for organ-specific promoter sequences. This has not been demonstrated experimentally in physiological conditions.

No independent lab has tested or validated the proposed organ-specific DNA-binding mechanism for any of these peptides.

Key Research Areas and Studies

Rat Prostatitis Model (1990s–2000s)

Khavinson et al., publication details not fully accessible: Prostamax administered for 15 days in a rat prostatitis (prostate inflammation) model. Results: reduced prostate swelling, decreased vascular congestion, decreased immune cell infiltration, and decreased scarring. Endpoint measurements suggest inflammatory resolution and tissue preservation. Specific PMID not identified in English-language PubMed search.

This is the primary functional efficacy study for Prostamax. It demonstrates that the peptide can affect prostate tissue inflammation in a rodent disease model—a more sophisticated endpoint than a simple biomarker change.

Chromatin Remodeling in Aged Cells (2000s–2010s)

Multiple studies from Khavinson's group report that Prostamax alters chromatin structure in cells from elderly donors—increased sister chromatid exchanges, increased nucleolar organizer regions, and reduced pericentromeric heterochromatin. These studies follow the same experimental template as the Livagen chromatin work (PMID 12533768), suggesting that the mechanism may be generalizable across the tetrapeptide subfamily.

Related Tissue-Extract Data

Prostatilen (the registered Russian pharmaceutical—a complex prostate tissue extract, not the synthetic Prostamax) has additional animal and clinical data. However, data on a related tissue extract does not constitute evidence for the synthetic peptide. The confusion between Prostatilen and Prostamax is important to address: they are different compounds with different levels of evidence.

The Khavinson Evidence Problem

This section addresses the central evidence challenge that applies to Prostamax and every compound in the Khavinson bioregulator family. Readers evaluating Prostamax cannot assess it without understanding this context.

Single-Lab Dependency

Virtually all published data on Prostamax originates from one institutional network: the St. Petersburg Institute of Bioregulation and Gerontology, directed by Vladimir Khavinson until his death in 2024. No Western lab—at any university, pharmaceutical company, or government research institute—has independently tested Prostamax's effects on prostate inflammation, gene expression, or any other endpoint.

Russian-Language Literature and Inaccessibility

The evidence base for Prostamax exists primarily in Russian-language publications not indexed on PubMed. The rat prostatitis study, the chromatin studies, and any clinical data that may exist are not accessible in English. This means the full evidence—such as it is—cannot be audited by readers who do not read Russian.

No Western Regulatory Review

Prostamax has never been submitted to the FDA, EMA, TGA, or Health Canada for review. It has no ClinicalTrials.gov entries. There is no regulatory file, no pharmacokinetic data, no dose-escalation study.

The Specificity Question: How Does One Amino Acid Change Target Completely Different Organs?

Prostamax (Lys-Glu-Asp-Pro) differs from Livagen (Lys-Glu-Asp-Ala) by a single amino acid at the C-terminus. Livagen targets the liver. Prostamax targets the prostate. Testagen (Lys-Glu-Asp-Gly) targets the testes. Pancragen (Lys-Glu-Asp-Trp) targets the pancreas.

The claim is that this one-residue substitution is responsible for organ-specific targeting. This would require that the peptides bind different promoter sequences in different cell types with high specificity. No experimental demonstration of this differential DNA binding has been published in Western-accessible literature.

The Replication Void and the Prostate-Specific Problem

Prostate health is among the most aggressively marketed wellness categories on the internet. Unvalidated ingredients claiming prostate benefit proliferate. This is the regulatory and editorial context in which Prostamax must be evaluated: a compound with single-source preclinical data, no human evidence, and a target tissue that attracts the most questionable marketing claims.

Claims vs. Evidence

The Human Evidence Landscape

There is no controlled human evidence for Prostamax. The compound has never been tested in a randomized, controlled, blinded trial in humans—in any country, under any regulatory framework.

Observational Use in Russia (Inaccessible)

The 2013 review (PMID 24003726) lists multiple Khavinson peptides among compounds studied clinically in Russia. Whether Prostamax was included in these clinical studies is unclear—the clinical data referenced in that review is published in Russian-language journals not indexed on PubMed and cannot be independently audited in English.

Confusion with Prostatilen

Readers and marketers frequently conflate Prostamax (the synthetic tetrapeptide) with Prostatilen (the tissue-extract pharmaceutical registered in Russia). This conflation artificially inflates Prostamax's evidence base. Prostatilen has clinical use data accumulated over ~30 years in Russia. Prostamax does not. The compounds are different.

What Would Need to Happen

For human evidence to emerge for Prostamax, a research group would need to: 1. Conduct a pharmacokinetic study establishing that the tetrapeptide is absorbed and reaches prostate tissue in humans 2. Conduct a dose-finding study establishing tolerable and biologically active doses 3. Conduct a randomized, controlled trial measuring prostate-specific endpoints (prostate symptom scores, biomarkers, or imaging) in a defined population with benign prostate hyperplasia or chronic prostatitis

None of these studies exist or are registered.

Safety, Risks, and Limitations

No Human Safety Data

No formal human safety or toxicology data exists for Prostamax in Western-accessible literature. The tetrapeptide consists of four common amino acids (lysine, glutamic acid, aspartic acid, and proline), which suggests a favorable safety profile—but "consists of safe building blocks" is not the same as "demonstrated to be safe."

Theoretical Safety Advantage

Ultrashort peptides are generally considered low-risk because they are rapidly degraded by ubiquitous peptidases. A tetrapeptide of four standard amino acids is unlikely to accumulate, cause immune reactions, or produce off-target receptor effects. This theoretical safety argument is plausible but not validated by formal toxicology studies.

Unknown Pharmacokinetics

The absorption, distribution, metabolism, and excretion (ADME) of Prostamax in humans is unknown. How much of an injected or orally administered tetrapeptide reaches the prostate? How much reaches intact cells? How much penetrates nuclei? These questions are fundamental and unanswered.

Prostate-Specific Consideration: The Risk of False Reassurance

Prostate health compounds that lack human evidence carry a specific risk: the possibility that men with undiagnosed prostate cancer or benign prostate hyperplasia (BPH) might delay or avoid seeking proper medical evaluation because they are taking an unproven supplement. This is not a direct toxicity risk. It is a healthcare-access risk.

Legal and Regulatory Status

FDA Status

Prostamax has never been approved, reviewed, or submitted to the FDA. It is not an authorized pharmaceutical ingredient in the United States. It is not recognized as a dietary supplement ingredient under DSHEA (Dietary Supplement Health and Education Act).

Russian Status

Prostamax itself is not a registered pharmaceutical in Russia. The related tissue-extract pharmaceutical Prostatilen (a complex mixture from prostate tissue) is a registered pharmaceutical in Russia—but it is a different compound with a different evidence base. This distinction is frequently confused in marketing materials and vendor websites.

WADA Status

Prostamax is not specifically listed on the WADA prohibited list. As a synthetic tetrapeptide, it may fall under S2 (Peptide hormones, growth factors, and related substances) depending on classification—but this is ambiguous for a four-amino-acid sequence with no established hormonal activity.

Market Availability

Prostamax is available through research peptide suppliers, typically as lyophilized powder labeled "for research purposes only." Purity, identity, and sterility are not regulated. The compound may be marketed as a wellness supplement in some jurisdictions without regulatory oversight.

Research Protocols and Formulation Considerations

Chemical Composition

Prostamax is a synthetic tetrapeptide: L-Lysyl-L-Glutamyl-L-Aspartyl-L-Proline. Molecular weight: ~473 Da. Molecular formula: C₂₁H₃₃N₅O₈.

Synthesis

Synthesized via standard solid-phase or solution-phase peptide synthesis. The tetrapeptide is straightforward to synthesize by modern peptide chemistry standards.

Stability

As a tetrapeptide, Prostamax is susceptible to degradation by aminopeptidases and carboxypeptidases present throughout biological fluids. Stability in solution is limited. Lyophilized powder is the standard storage form. Light and moisture sensitivity are expected for peptides with proline residues.

Formulation

Research-grade Prostamax is typically supplied as lyophilized powder, reconstituted with bacteriostatic water or saline. Some vendors offer capsule formulations intended for oral administration.

Dosing in Published Research

Route of Administration

The rat prostatitis study used a route that is not specified in accessible English-language abstracts. Based on the pattern of other Khavinson bioregulator studies, subcutaneous injection is likely.

Doses in Published Studies

The rat prostatitis study: 15-day regimen. Specific dose not stated in available English abstracts. The related Prostatilen pharmaceutical (complex extract, not synthetic peptide) is dosed at standard pharmaceutical concentrations (typically 50 mg suppositories or 30 mg IM injections in Russian formulations).

No human dose has been established by any published study.

Pharmacokinetics

Unknown in humans. The half-life of a free tetrapeptide in human plasma is expected to be very short (minutes to hours) due to rapid enzymatic degradation by peptidases.

Dosing in Self-Experimentation Communities

WHY NEARLY EMPTY: Prostamax has minimal community adoption compared to mainstream peptides like BPC-157, TB-500, or MK-677. The Khavinson bioregulator market is extremely niche—primarily driven by longevity enthusiasts familiar with Russian peptide science and willing to navigate the evidence desert. No systematic community dosing data, dose-response reports, or protocol comparisons exist for Prostamax specifically.

Reported Community Doses (Unverified)

Vendor websites occasionally suggest doses in the range of 100–200 mcg/day subcutaneously or 200–500 mcg/day orally. These doses are not derived from any published dose-finding study. They appear to be extrapolated from doses of other Khavinson bioregulators (Vilon, Thymogen) or derived from the Prostatilen pharmaceutical concentration (which is a tissue extract, not the synthetic peptide).

Frequency and Duration

Community protocols, where mentioned, typically suggest cycles of 10–20 days, with rest periods between cycles. This cycling pattern mirrors Russian bioregulator supplement protocols but has no published pharmacological basis.

Combination Stacks

Research into Prostamax combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Prostamax with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) developed by Vladimir Khavinson as part of the bioregulator family—a family of organ-targeted peptides proposed to modulate gene expression by interacting directly with DNA. It is one of four tetrapeptides that share the same first three amino acids (Lys-Glu-Asp) and differ only in the C-terminal residue, with the claim that this single-residue difference directs the peptide to different organs.

The preclinical evidence for Prostamax is the thinnest in this subfamily. One rat prostatitis model showed reduced inflammation and scarring—a functional animal study, not just a biomarker change. Chromatin studies reported changes in heterochromatin structure consistent with the broader Khavinson mechanism hypothesis. But there is no independent replication, no human data, no pharmacokinetic characterization, no dose-finding study, and no English-language PubMed-indexed studies unique to Prostamax.

The compound is not to be confused with Prostatilen, a registered Russian pharmaceutical made from prostate tissue extract—a related but different compound with clinical use history that spans decades. The confusion between these two is frequent in marketing materials and vendor descriptions.

Verdict Recapitulation

Prostamax earns "Thin Ice" rather than "Eyes Open" because its evidence base is thinner than even the average Tier 4 compound in this family. One rat model (functional endpoint, which is good), chromatin studies (consistent with mechanism, which is good), but complete absence of any independent replication, any human data, any pharmacokinetic characterization, and any English-language PubMed-indexed studies unique to the compound (which is bad). The target tissue—the prostate—is uniquely susceptible to marketing hype and unvalidated claims, which raises the editorial bar. The specificity question (how does a one-residue amino acid substitution target completely different organs?) remains unresolved. Prostamax sits at the thin end of the Khavinson spectrum and demands particular scrutiny.

For readers considering Prostamax, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Prostamax

Further Reading and Resources

If you want to go deeper on Prostamax, the evidence landscape for khavinson bioregulators peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Khavinson Bioregulators Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Prostamax — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Khavinson VKh, Anisimov VN, et al. "Prostamax peptide bioregulator effects in rat prostatitis models." [Publication details not fully accessible in English-language PubMed search. Published in Russian-language literature from St. Petersburg Institute.]
2. Khavinson VKh, Lezhava TA, et al. "Effects of Livagen peptide on chromatin activation in lymphocytes from old people." Bulletin of Experimental Biology and Medicine. 2002;134(4):389–392. PMID 12533768 (Cluster-wide chromatin reference—template for Prostamax chromatin studies)
3. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies." Advances in Gerontology. 2012;25(4):696–708. PMID 23734519
4. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results." Advances in Gerontology. 2013;26(1):20–37. PMID 24003726
5. Deigin VI, et al. "Development of peptide biopharmaceuticals in Russia." Pharmaceutics. 2022;14(4):716. PMC: 9030433

---